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Background: Altering rotavirus vaccine schedules may improve 
vaccine performance in low- and middle-income countries. We ana-
lyzed data from clinical trials of the monovalent (RV1) and pentava-
lent (RV5) rotavirus vaccines in low- and middle-income countries to 
understand the association between vaccine dose timing and severe 
rotavirus gastroenteritis incidence.
Methods: We assessed the association between variations in rotavi-
rus vaccine administration schedules and severe rotavirus gastroen-
teritis risk. We used the complement of the Kaplan–Meier survival 
estimator to estimate risk differences for different schedules. To 
adjust risk differences (RDs) for confounding, we calibrated esti-
mates in the vaccinated arm using estimates from the placebo arm.
Results: There were 3,114 and 7,341 children included from the 
RV1 and RV5 trials, respectively. The 18-month adjusted severe 
rotavirus gastroenteritis risk was 4.0% (95% confidence interval 
[CI] = 1.1, 7.1) higher for those receiving their first RV5 dose at <6
versus ≥6 weeks. For RV1, there was a 4.0% (95% CI = 0.0, 8.2)
increase in 12-month adjusted risk for a 4- versus 6-week interval
between doses. Further analysis revealed those receiving their first
RV5 dose at 3–4 and 5–7 weeks had 2.9% (95% CI = 0.8, 5.3) and
1.3% (95% CI = −0.3, 3.0), respectively, higher risk compared with
those at 9–12 weeks. Those receiving their first dose at 8 weeks had
the lowest risk (RD: −2.6% [95% CI = −5.4, −0.1]) compared with
those at 9–12 weeks.
Conclusions: A modest delay in rotavirus vaccination start and
increase in interval between doses may be associated with lower
severe rotavirus gastroenteritis risk in low- and middle-income
countries.
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Timing of Rotavirus Vaccine Doses and Severe Rotavirus 
Gastroenteritis Among Vaccinated Infants in Low- and 
Middle-income Countries
Joann F. Gruber,a Sylvia Becker-Dreps,a,b Michael G. Hudgens,c M. Alan Brookhart,a 
James C. Thomas,a,d and Michele Jonsson Funka
Despite the success of rotavirus vaccines at reducing healthcare encounters including hospitalizations,1–3 
rotavirus vaccine effectiveness remains lower in low- and 
middle-income countries than in high-income countries.4,5 
Many factors may contribute this lower vaccine effective-
ness including concomitant vaccination with oral polio vac-
cine,6,7 malnutrition,8,9 interference by transplacental maternal 
antibodies,10,11 and environmental enteropathy and the infant 
microbiota.12–14
Some factors shown to decrease rotavirus vaccine perfor-
mance may be overcome by altering rotavirus vaccine sched-
ules. A few studies have investigated the influence of vaccine 
schedules on vaccine performance,10,11,15 but these studies have 
generally been restricted to immunologic endpoints. Because 
there is no known correlate of protection for antirotavirus immu-
noglobulin A (IgA) levels,16,17 there is still uncertainty about the 
effect alternative schedules have on clinical endpoints. No data 
have been reported on the effect of timing of commonly used 
rotavirus vaccines as they are routinely administered (i.e., two 
doses of the monovalent [RV1, Rotarix; GlaxoSmithKline Bio-
logicals, Rixensart, Belgium] and three doses of the pentavalent 
[RV5, RotaTeq; Merck & Co, Inc.; Kenilworth, NJ] rotavirus 
vaccines) using clinical endpoints.
We analyzed data from two large rotavirus vaccine trials 
to understand the association of timing of rotavirus vaccine 
doses and incidence of severe rotavirus gastroenteritis among 
children in low- and middle-income countries.
METHODS
Parent Study Data
This analysis used data from two randomized, phase III, 
placebo-controlled, multicenter clinical trials of RV1 and RV5 
(Clinical Trial Number: NCT00241644 and NCT00362648, 
respectively) conducted in low- and middle-income countries. 
The trials have been described in depth elsewhere,18–20 but a 
brief summary of each trial is below.
The RV1 clinical trial was conducted in South Africa and 
Malawi from 2005 to 2009. Healthy infants aged 5–10 weeks 
were enrolled and randomized to receive three placebo doses, a 
placebo dose followed by two RV1 doses, or three RV1 doses 
at approximately 6, 10, and 14 weeks of age. Enrolled infants 
were actively followed for occurrence of gastroenteritis from 
enrollment until study conclusion at 1 year of age with a subset 
followed for up to 2 years of age. Study staff visited parents or 
guardians at the homes of participants weekly to collect diary 
cards and also visited health clinics serving the study popula-
tion. Stool samples were collected and tested for rotavirus using 
an enzyme-linked immunosorbent assay (Rotaclone, Meridian 
Biosciences, Cincinnati, OH) followed by reverse transcriptase 
polymerase chain reaction (RT-PCR) confirmation. Gastroen-
teritis was defined as three or more, looser than normal stools 
within a 24-hour period. Rotavirus gastroenteritis severity was 
determined using the 20-point Vesikari score.21
The RV5 study was conducted in Ghana, Kenya, Mali, 
Bangladesh, and Vietnam from 2007 to 2009. Infants 4–12 
weeks of age were enrolled and randomly assigned to receive 
three doses of vaccine or placebo at approximately 6, 10, and 
14 weeks of age. During the study, there was active surveil-
lance for gastroenteritis at local clinics and hospitals. Any par-
ticipant presenting with gastroenteritis provided a stool sample 
for testing of rotavirus using an enzyme immunoassay followed 
by RT-PCR confirmation. Gastroenteritis was defined as three 
or more watery or looser than normal stools within a 24-hour 
period or forceful vomiting. rotavirus gastroenteritis severity 
was classified using the 20-point modified Vesikari score.21–23
Study Data
We analyzed data from the placebo and vaccinated arms 
of each trial as they are recommended for use (two doses of RV1 
and three doses of RV5). In the RV1 trial, we included infants 
randomized to receive placebo or two doses of RV1 (precise 
schedules were three placebo doses or one placebo dose and two 
RV1 doses). In the RV5 trial, we included infants randomized to 
receive three doses of placebo or three doses of RV5. Each trial 
was analyzed separately, but the results are presented in parallel. 
This research was approved by the University of North Carolina 
at Chapel Hill Institutional Review Board (15–0401).
Study Design Overview
We used a modified version of the study design 
described by Hernán et al24 to understand whether timing of 
rotavirus vaccine doses, which was not randomized, was asso-
ciated with risk of severe rotavirus gastroenteritis. We began 
by defining five different aspects of vaccine timing. For a spe-
cific aspect of timing (e.g., timing of first dose), we compared 
two or more predefined schedules related to that aspect of tim-
ing (e.g., first dose given at <10 vs. ≥10 weeks). We compared 
the schedules by assessing the cumulative risk of severe rota-
virus gastroenteritis on an age-specific time scale to include 
severe episodes from 12 weeks of age. We did this by parti-
tioning the follow-up time of infants such that infants could 
contribute person-time and severe events to more than one of 
the predefined schedules so schedules with delayed vaccine 
doses included severe episodes after 12 weeks of age in their 
estimated associations. After partitioning follow-up time and 
events, we estimated the association between each schedule 
and incidence of severe rotavirus gastroenteritis. We used the 
estimated associations of schedules in the placebo arm, which 
should have a null effect, to calibrate the estimates within the 
rotavirus-vaccinated arm to obtain adjusted estimates of the 
associations. This approach is similar to the negative control 
design described by Tchetgen Tchetgen.25
Defining Schedules
We created and compared simplified schedules to 
understand the aspects of timing that may be associated with 
risk of severe rotavirus gastroenteritis. Because of the numer-
ous combinations of schedules received, we could not simply 
compare the schedules received in each trial. Instead, we 
classified the timing of doses a priori using five main aspects 
of dose timing: (1) timing of first-dose holding interval(s) 
between doses constant at 4 to 6 weeks, (2) timing of first 
dose, (3) timing of last dose, (4) length of interval(s) between 
doses, and (5) number of doses received at ≥10 weeks of age. 
For each aspect of timing, we defined and compared two or 
more schedules. All schedules were developed based on bio-
logic plausibility, the potential for realistic interventions (e.g., 
alterations in rotavirus schedules that would fit at times rou-
tine vaccines are given as part of the Expanded Program on 
Immunization), and the nature of the data. The schedules for 
each aspect of timing are specified in Table 1 and a detailed 
description of each schedule can be found in eTable 1 (http://
links.lww.com/EDE/B397). Owing to the number of associa-
tions estimated, we chose our primary aspect of timing a priori 
to be the timing of the first dose holding interval(s) between 
doses constant at 4–6 weeks. Completed weeks of age were 
used for all schedule definitions (e.g., 6 weeks and 5 days of 
age was categorized as 6 weeks of age).
Outcome
We classified the outcome, first episode of severe rota-
virus gastroenteritis, as infants experiencing gastroenteritis 
with a Vesikari or modified Vesikari score of ≥11. For all 
analyses, we analyzed data on an age-specific time scale with 
TABLE 1. Predefined Rotavirus Vaccine Schedules for Each Aspect of Dose Timing





(Weeks) Timing of Dose 2 Timing of Dose 3
First dose  
with 4–6 weeks  
between doses
1,167 1,073 RV5 3–6 4–6 weeks after first dose 4–6 weeks after second dose
1,669 1,516 RV5 7–9 4–6 weeks after first dose 4–6 weeks after second dose
784 720 RV5 10–12 4–6 weeks after first dose 4–6 weeks after second dose
1,299 1,212 RV1 10–12 4–6 weeks after first dose NA
207 166 RV1 13–16 4–6 weeks after first dose NA
First dose 519 506 RV5 <6 ≤10 weeks after first dose ≤10 weeks after second dose
3,147 3,063 RV5 ≥6 ≤10 weeks after first dose ≤10 weeks after second dose
2,882 2,805 RV5 <10 ≤10 weeks after first dose ≤10 weeks after second dose
784 764 RV5 ≥10 ≤10 weeks after first dose ≤10 weeks after second dose
Last dose 1,527 1,216 RV5 ≤7 ≤11 weeks of age ≤15 weeks of age
3,520 2,353 RV5 ≤12 ≤10 weeks after first dose >15 weeks of age and ≤10
weeks after second dose
1,048 420 RV1 ≤11 ≤15 weeks of age NA





2,589 1,310 RV5 ≤12 4 weeks after first dose 4 weeks after second dose
3,345 1,453 RV5 ≤12 4 or 5 weeks after first dosec 4 or 5 weeks after second 
dosec
3,474 546 RV5 ≤12 4, 5, or 6 weeks after first dosed 4, 5, or 6 weeks after 
second dosed
1,559 337 RV1 ≤16 4 weeks after first dose NA
1,559 926 RV1 ≤16 5 weeks after first dose NA
1,559 167 RV1 ≤16 6 weeks after first dose NA
Number of 
doses ≥  
10 weeks of agee
1,030 2 RV5 <10 <10 weeks of age <10 weeks of age
3,666 397 RV5 <10 <10 weeks of age ≥10 weeks of age  
and ≤32 weeks of age
3,271 2,432 RV5 <10 ≥10 weeks of age and  
≤32 weeks of age
≥10 weeks of age  
and ≤32 weeks of age
784 765 RV5 ≥ 10 ≥10 weeks of age and  
≤32 weeks of age
≥10 weeks of age  
and ≤32 weeks of age
aNumber of infants beginning follow-up at 12 weeks of age in this schedule. Total sample size across schedules for an aspect of timing can sum to more than the total number of 
vaccinated infants in each trial because infants can begin in >1 schedule.
bNumber of infants being followed for severe rotavirus gastroenteritis for a particular schedule at 6 months of age.
cAt least one interval between the three doses must be 5 weeks.
dAt least one interval between the three doses must be 6 weeks.
eOther timing of doses resulting in the same number of doses received ≥10 are possible and are included in eTable 1.
NA indicates not applicable.
follow-up beginning at 12 weeks of age (the latest time any 
infant enrolled in either trial). As mentioned above, we par-
titioned the follow-up time of infants such that infants could 
contribute person-time and severe gastroenteritis events to 
more than one schedule until the timing of their actual doses 
deviated from the schedule(s). This approach allowed us to 
include any severe events occurring after 12 weeks of age. 
Figure 1 presents three hypothetical infants and how their 
person-time and severe rotavirus gastroenteritis episodes were 
partitioned for timing of last dose. In this example, all infants 
contributed person-time to both predefined schedule until the 
actual timing of their last doses deviated from the predefined 
schedule. For example, infant A experienced a severe episode 
at 14 weeks of age, and this event was included in both sched-
ules, because at 14 weeks of age, the timing of infant A’s last 
dose was consistent with both predefined schedules. Addi-
tional details of the approach are included in eTable 2 (http://
links.lww.com/EDE/B397).
Covariates
We categorized covariate data on demographic infor-
mation; breastfeeding and growth status; and infection status, 
antibiotic use, and other vaccinations. We categorized growth 
status using the World Health Organization criteria.26 We clas-
sified infection status, antibiotic use, and concomitant vacci-
nation using medical histories.
Statistical Analysis
To estimate the association between timing of rotavi-
rus vaccine doses and incidence of severe rotavirus gastro-
enteritis, we estimated risk differences (RDs) and risk ratios 
(RRs) between different schedules for each aspect of timing at 
6, 12, and 18 months of age using cumulative risk estimates 
obtained from the complement of the Kaplan–Meier survival 
estimator at those time points.27 We chose a priori to focus 
on 12 months of age as our primary time point of interest, 
because that provided adequate time for severe gastroenteri-
tis events to occur while allowing a majority of participants 
to remain in the cohorts. We did not estimate RDs or RRs at 
specific time points if any schedule had fewer than five severe 
events at that time point. We also estimated hazard ratios using 
Cox proportional hazard models.
There was potential for bias in the association between 
dose timing and severe rotavirus gastroenteritis, because of 
confounding and administrative censoring in the study design. 
Data from the placebo arms was used as a negative control to 
adjust for both potential sources of bias. Because the timing 
of placebo doses should not influence the incidence of severe 
rotavirus gastroenteritis in the placebo arm, any association 
observed would be owing to bias. This association provided 
an estimate of amount of bias expected from uncontrolled 
confounding within the vaccinated arms, assuming potential 
uncontrolled confounders influencing the timing of receipt of 
doses in the placebo arms were the same confounders as those 
in the rotavirus-vaccinated arms. Associations in the placebo 
arm were used to calibrate (i.e., adjust) the estimates among 
those in the vaccinated arm. The directed acyclic graphs in 
eFigure 1 (http://links.lww.com/EDE/B397) provide a con-
ceptual diagram of this approach.
Before calibrating estimates, we empirically verified that 
imbalances in measured covariates between schedules were 
similar in the placebo and vaccinated arms using standard-
ized mean differences. Standardized mean differences were 
calculated as (p1 − p2)/[{p1(1 − p1) + p2(1 − p2)}/2]1/2, where 
p1 was the proportion (or mean) of the binary covariate for a 
specific schedule (e.g., first dose at <6 weeks), and p2 was the 
proportion in a different schedule (e.g., first dose at ≥6 weeks). 
If the imbalance in covariates was similar (<10% difference) 
between the placebo and vaccinated arms, we assumed cali-
bration of the estimates in the vaccinated arm would yield a 
sufficiently adjusted estimate of the associations.
To calibrate (i.e., adjust) the associations of rotavirus 
vaccine dose timing, we estimated RD and RR measures 
comparing schedules for each aspect of timing, as described 
above, for both the placebo and vaccinated arms of each trial. 
FIGURE 1. Example of the person-time 
and event categorization for three hypo-
thetical infants. RVGE indicates rotavirus 
gastroenteritis.
We then calibrated the estimates among those vaccinated with 
the estimates among those in the placebo arms by subtracting 
the difference measures and dividing the ratio measures (i.e., 
difference in differences and ratio of ratios).28 A nonparamet-
ric bootstrap with 2,000 sample draws with replacement was 
used to obtain the point estimates and 95% empirical confi-
dence intervals.29 The median of the distribution of calibrated 
estimates was reported for the difference and ratio estimates, 
and the 2.5th and 97.5th percentiles of the distribution were 
reported for the lower and upper bounds of the 95% empirical 
confidence intervals.
We conducted additional post hoc analyses to assess 
the association between timing of first dose and incidence of 
severe rotavirus gastroenteritis. We estimated the 12-month 
RD of severe gastroenteritis by week of age at first dose, 
requiring ≥100 infants in each stratum. We then collapsed 
across ages with similar RDs to estimate the RDs more pre-
cisely. We also estimated the 12-month RD between a 6/10/14 
and 8/12/16 week schedule for RV5. All analyses were per-
formed using SAS Clinical Trial Data Transparency (version 
4.5.2; SAS Institute, Inc., Cary, NC).
RESULTS
There were 3,114 and 7,341 children included in this 
analysis from the RV1 and RV5 trials, respectively (Table 2). 
Infants were followed for a median time of 286 and 301 days 
after 12 weeks of age in both the placebo and RV1-vaccinated 
arms, respectively. Median follow-up was 483 days after 12 
weeks of age in both the placebo and RV5-vaccinated arms. 
A total of 154 (100 and 54 in placebo and RV1 arms, respec-
tively) and 324 (205 and 119 in placebo and RV5 arms, respec-
tively) severe rotavirus gastroenteritis events occurred in the 
RV1 and RV5 trials, respectively.
The distributions of measured covariates between sched-
ules for each aspect of timing were similar for the placebo 
and rotavirus-vaccinated arms (data available upon request). 
This provided empirical evidence for our assumptions for 
using calibration for adjustment. However, one comparison, 
first dose of RV1 with 4–6 weeks between doses, had a num-
ber of deviations, which may indicate presence of residual 
confounding.
First Dose With 4–6 Weeks Between Doses
The adjusted risk of severe rotavirus gastroenteritis was 
about 2% higher for those infants receiving their first R V5 
dose at 3–6 weeks of age compared with 10–12 weeks of age 
(holding intervals between all subsequent doses at 4–6 weeks) 
[12-month RD: 2.1% (95% confidence interval [CI] = 0.1, 
4.0); 12-month RR: 2.2 (95% CI = 0.7, 6.7)] (Figures 2 and 3).
First Dose
The 18-month adjusted risk of severe rotavirus gastro-
enteritis was 4.0% (95% CI = 1.1, 7.1) higher for those receiv-
ing their first RV5 dose at <6 versus ≥6 weeks of age. The 
18-month RR was 2.4 (95% CI = 1.3, 4.8).
 
Last Dose
Infants receiving their last RV5 doses at ≤15 versus >15 
weeks of age had almost a 2% increase in 12-month adjusted 
risk of severe rotavirus gastroenteritis (12-month RD: 1.9% 
[95% CI = 0.6, 3.2]; 12-month RR: 1.7 [95% CI = 0.7, 4.2]). 
This was slightly attenuated and less precise for RV1 (12-
month RD: 1.4% [95% CI = −1.1, 4.1]; 12-month RR: 0.7 
[95% CI = 0.1, 2.2]).
Interval Between Doses
For RV1, there was a 4.0% (95% CI = 0.0, 8.2) increase in 
12-month adjusted risk for a 4- versus 6-week interval between 
doses (12-month RR: 3.6 [95% CI = 0.9, 31.6]). This association 
was diminished to about 2% when comparing a 5- to 6-week 
interval, but this estimate was imprecise (12-month RD: 1.9% 
[95% CI = −2.2, 5.9]; 12-month RR: 4.5 [95% CI = 0.9, 46.5]).
Number of Doses ≥10 Weeks of Age
Those receiving only one dose of RV5 at ≥10 weeks of age 
had a higher adjusted risk of severe rotavirus gastroenteritis com-
pared with those receiving three doses at ≥10 weeks (12-month 
RD: 2.6% [95% CI = 0.7, 4.7]; 12-month RR: 4.8 [95% CI = 0.7, 
75.3]). When the analysis comparing one versus three doses of 
RV5 at ≥10 weeks of age excluded infants missing the second or 
third dose of vaccine, the effect seen was similar (12-month RD: 
2.5% [95% CI = 0.5, 4.7]; 12-month RR: 4.7 [95% CI = 0.7, 70.5]).
Additional Results
The estimated uncalibrated cumulative risk of severe 
rotavirus gastroenteritis stratified by schedule and treatment 
status (i.e., placebo or vaccinated) is shown for all compari-
sons in eFigures 2–10 (http://links.lww.com/EDE/B397). 
Hazard ratios are presented in eFigure 11 (http://links.lww.
com/EDE/B397) and were similar to RRs. Calibrated, uncali-
brated, and placebo RDs and RRs at 12 and 18 months are 
presented in eFigures 12 and 13 (http://links.lww.com/EDE/
B397), respectively. RDs and RRs were not estimated for any 
comparisons at 6 months of age and for first dose at <6 versus 
≥6 weeks of age schedule at 12 months of age, because there 
were fewer than five events for at least one schedule.
The post hoc assessment of the dose–response relation-
ship between timing of first dose and incidence difference of 
severe rotavirus gastroenteritis is presented in Figure 4. Those 
receiving their first RV5 dose at 3–4 and 5–7 weeks had 2.9% 
(95% CI = 0.8, 5.3) and 1.3% (95% CI = −0.3, 3.0), respec-
tively, higher severe gastroenteritis risk compared with those 
at 9–12 weeks. Those receiving their first dose at 8 weeks had 
the lowest risk (RD: −2.6% [95% CI = −5.4, −0.1]) compared 
with those at 9–12 weeks. In addition, the estimated 12-month 
RD for a 6/10/14 compared with 8/12/14 week schedule of 
RV5 was 7.1% (95% CI = 2.9, 11.8).
DISCUSSION
Comparisons from the RV5 trial indicated earlier vacci-
nation of the first RV5 dose resulted in a higher risk of severe 
TABLE 2. Characteristics of the Trial Populations
Infant Characteristics









Median length of follow-up in 
days from 12 weeks of age
301 286 483 483
First severe rotavirus 
gastroenteritis episode
54 100 119 205
Age in weeks at vaccine or 
placebo receipt
 Dose 1a, mean (SE) 11.2 (0.03) 11.3 (0.03) 7.6 (0.03) 7.5 (0.03)
 Dose 2b, mean (SE) 16.2 (0.04) 16.3 (0.04) 12.2 (0.04) 12.1 (0.04)
 Dose 3c, mean (SE) — — 16.7 (0.04) 16.7 (0.04)
Demographic
 Female sex (%) 48.8 48.6 48.6 49.7
 African race (%) 97.2 96.8 72.3 72.4
 Asian race (%) — — 27.6 27.6
Growth status at enrollment
 Stunted (%) 22.6 21.7d 10.1 10.4e
 Underweight (%) 3.9 4.4 11.5 11.2
 Wasting (%) 3.7d 4.3d 23.1d 20.9d,e
Exclusively breastfed
 At dose 1 (%) — — 80.0 81.6
 At dose 2 (%) — — 75.2d 74.7
 At dose 3 (%) — — 69.9 70.1d
≥1 infection(s)
 At dose 1 (%) 0.5 0.9 5.5 5.6
 At dose 2 (%) 0.3 0.4 0.5 0.6
 At dose 3 (%) — — 1.1 1.3
≥1 antibiotic usedf
 At dose 1 (%) 12.9 14.1 2.2 2.8
 At dose 2 (%) 15.5 14.6 5.6 5.2
 At dose 3 (%) — — 6.2 6.1
Routine vaccines
≥1 BCG vaccine
  At dose 1 (%) — — 21.9 22.0
≥1 DTP-HB/HIB vaccineg
 At dose 1 (%) 99.3 99.3 45.7 47.0
 At dose 2 (%) 99.1 99.5 43.6 43.8
 At dose 3 (%) — — 42.0 42.2
≥1 oral polio vaccine
 At dose 1 (%) 99.3 99.3 54.1 55.6
 At dose 2 (%) 99.2 99.5 51.1 51.0
 At dose 3 (%) — — 48.2 48.1
aThere were 25 and 21 in the placebo and RV1 arms, respectively, missing dose 1.
bThere were 63 and 45 in the placebo and RV1 arms, respectively, missing dose 2. There were 17 and 10 in the placebo and RV5 arms, respectively, missing dose 2.
cThere were 57 and 47 in the placebo and RV5 arms, respectively, missing dose 3.
dMissing 1–15 observations, excluding those missing doses of vaccine or placebo.
e Excluding Bangladesh.
fExcluding topical antibiotics.
gOr DTaP & HB, which were the standard vaccines given in Asian countries.
BCG indicates Bacillus Calmette–Guérin; DTaP, diphtheria and tetanus toxoids and acellular pertussis; DTP-HB/HIB, diphtheria-tetanus-pertussis-Hepatitis B and -Haemophilus 
influenza B.
of age. In a previous analysis conducted by the first author, 
there was heterogeneity of vaccine efficacy (comparing vac-
cinated infants to unvaccinated infants) for those with a first 
dose of RV5 received at <8 weeks compared with ≥8 weeks 
FIGURE 2. Uncalibrated and calibrated RDs and 95% CIs.
FIGURE 3. Uncalibrated and calibrated RRs and 95% CIs.
rotavirus gastroenteritis with this risk declining with later 
vaccination until approximately 8 weeks of age. Importantly, 
these associations were present even when accounting for the 
occurrence of severe gastroenteritis episodes after 12 weeks 
between doses and severe gastroenteritis. To our knowledge, 
no studies have investigated the association between interval 
length and outcomes for rotavirus vaccines. A study of intervals 
between oral polio vaccine doses in Bangladesh reported simi-
lar seroconversion proportions among those vaccinated with a 
2- versus 4-week interval between doses.32 However, serocon-
version proportions for some poliovirus types were lower for
the 2- versus 4-week intervals. A longer delay between doses
may provide a greater booster effect for oral vaccines, includ-
ing RV1. However, the underlying mechanism for the observed
association was not investigated and remains unknown.
There were a number of limitations of this research. 
Because this was a reanalysis of previously collected data, 
there were restrictions on the comparisons we could assess. 
Also, we were unable to account for events that occurred 
before 12 weeks of age. In the RV5 cohort, no events occurred 
before 12 weeks of age, but three events did occur before 12 
weeks of age in the RV1 trial (one and two in the placebo and 
RV1 arms, respectively). eTable 3 (http://links.lww.com/EDE/
B397) provides estimates from the placebo arms of each trial 
of the expected number of severe rotavirus gastroenteritis epi-
sodes that would occur by delaying vaccination start by 2 or 4 
weeks. We were also unable to stratify by continent or country 
owing to the relatively few number of severe gastroenteritis 
episodes. There may be important differences between low- 
and middle-income countries that we could not assess. In 
addition, there may have been residual confounding of some 
estimates that we were unable to account for in this analysis. 
Although the vast majority of schedules had similar covariate 
imbalances in the placebo and vaccinated arms, there were a 
few comparisons that did not deviate in a similar manner. This 
means that after calibration of estimates, these estimates may 
have had some residual confounding. In addition, because 
we were unsure of which aspect of timing could potentially 
be associated with risk of severe rotavirus gastroenteritis, 
we defined a priori a number of schedules to compare for 
each aspect of timing. These multiple comparisons may have 
resulted in observing associations by random chance.
Despite these limitations, there were a number of 
strengths of this study. The data from these trials allowed us to 
assess how the timing of rotavirus doses relates to the occur-
rence of severe rotavirus gastroenteritis, which has not been 
previously reported. The study had four notable advantages: 
(1) our study used data from two trials of two rotavirus vac-
cines to understand the association between rotavirus vaccine
timing, (2) the sample sizes of the trials were large enough
to assess severe gastroenteritis as the outcome of interest, (3)
we were able to use a novel study design to include rotavirus
episodes after 12 weeks of age to ensure later schedules were
penalized for any early episodes that occurred before receipt
of the vaccine, and (4) data in the placebo arms were lever-
aged as a negative control to adjust estimates of the associa-
tion between timing of rotavirus vaccine doses and incidence
of severe gastroenteritis.
FIGURE 4. Post hoc analysis of 12-month calibrated RDs and 
95% CIs for timing of first RV5 dose (referent 9–12 weeks).
of age.9 This analysis found a similar pattern when account-
ing for severe gastroenteritis episodes after 12 weeks of age 
and comparing different schedules among vaccinated infants. 
The results were consistent with trials investigating alternative 
rotavirus schedules reporting immunologic endpoints.30 Vac-
cination with RV1 at 10/14 versus 6/10 weeks of age resulted 
in higher seroconversion percentages. At 18 weeks of age, the 
seroconversion percent difference comparing a 10/14 versus 
6/10 week schedule was 12.8% (95% CI = 1.2, 23.2) in Ghana 
and 10.1% (95% CI = −0.4, 20.3) in Pakistan.10,11
Lower incidence of severe rotavirus gastroenteritis with 
delays in first rotavirus vaccine dose could be owing to a num-
ber of biologic factors including a decline in transplacentally 
acquired antirotavirus immunoglobulin G (IgG) antibodies or 
changes in the microbiota that allow for a stronger immune 
response with slightly older ages at first dose. In Ghana and 
Pakistan, there was higher seroconversion among infants in 
the lowest compared with highest quartile of prevaccination 
IgG levels.10,11 In addition, a case–control study of 6-week-
old Ghanaian infants found RV1 vaccine responders (post-
vaccination IgA antibody levels ≥20 IU/ml) had microbiotas 
more closely resembling Dutch infants than Ghanaian nonre-
sponders (postvaccination IgA antibody levels <20 IU/ml).13 
It may be possible such differences in microbiota between 
responders and nonresponders can be overcome with age, 
leading to improved vaccine response when vaccinated at 
slightly later ages. However, a study in Vellore, India, reported 
similar immunologic response to RV1 regardless of the pres-
ence of enteropathogens at the time of vaccination.31 There-
fore, the intestinal microbiota may not be the mechanism by 
which the association between timing of rotavirus vaccine 
dose and severe gastroenteritis is mediated.
We also found an increase in risk of severe rotavirus gas-
troenteritis for those infants with a 4-week interval between 
RV1 doses compared with a 6-week interval between doses. 
For RV5, there was no association between length of 
interval 
In this reanalysis of two clinical trials of rotavirus vac-
cines in low- and middle-income countries, we found there 
was an association between rotavirus vaccine dose timing 
and incidence of severe rotavirus gastroenteritis. These data 
suggest a modest delay in RV5 start and increase in interval 
between RV1 doses, when the series begins at approximately 
10 weeks of age, may improve rotavirus vaccines performance 
in low- and middle-income countries. However, the decision 
to delay rotavirus vaccination needs to be carefully considered 
in conjunction with early rotavirus exposures and potential 
missed vaccination opportunities to fully evaluate the poten-
tial benefits of delaying rotavirus vaccination start in low- and 
middle-income countries.
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